Skip to main content

3 articles related to "Her2 Targeting"

No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.

Articles

Review

Published on 15 Mar 2022

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

in Molecular Diagnostics and Therapeutics

Konstantinos Venetis
Edoardo Crimini
Elham Sajjadi
Chiara Corti
Elena Guerini-Rocco
Giuseppe Viale
Giuseppe Curigliano
Carmen Criscitiello
Nicola Fusco

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2022.834651

56,081 views
134 citations

Case Report

Published on 15 Nov 2022

Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma

in Cancer Immunity and Immunotherapy

Zhenying Xu
Jiaman Ma
Ting Chen
Yu Yang

Frontiers in Immunology

doi 10.3389/fimmu.2022.978266

5,951 views
16 citations

Original Research

Published on 22 Feb 2024

Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients

in Pharmacology of Anti-Cancer Drugs

Kejia Zhu
Yao Chang
Delong Zhao
Andong Guo
Jishuang Cao
Chenrui Wu
Yong Guan
Sentai Ding

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1355081

6,859 views
12 citations